We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting myeloid-derived suppressor cells for cancer immunotherapy.
- Authors
Liu, Yijun; Wei, Guowei; Cheng, Wesley A.; Dong, Zhenyuan; Sun, Han; Lee, Vincent Y.; Cha, Soung-Chul; Smith, D. Lynne; Kwak, Larry W.; Qin, Hong
- Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with an immune suppressive phenotype. They represent a critical component of the immune suppressive niche described in cancer, where they support immune escape and tumor progression through direct effects on both the innate and adaptive immune responses, largely by contributing to maintenance of a high oxidative stress environment. The number of MDSCs positively correlates with protumoral activity, and often diminishes the effectiveness of immunotherapies, which is particularly problematic with the emergence of personalized medicine. Approaches targeting MDSCs showed promising results in preclinical studies and are under active investigation in clinical trials in combination with various immune checkpoint inhibitors. In this review, we discuss MDSC targets and therapeutic approaches targeting MDSC that have the aim of enhancing the existing tumor therapies.
- Subjects
GENE targeting; SUPPRESSOR cells; CANCER immunotherapy; CANCER invasiveness; OXIDATIVE stress
- Publication
Cancer Immunology, Immunotherapy, 2018, Vol 67, Issue 8, p1181
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-018-2175-3